Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 17/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432463 | 1.00 | FOLH1 (0.48) | FOLH1ENPEP | |
| SCHEMBL29709563 | 0.96 | FOLH1 (0.44) | FOLH1ENPEP | |
| SCHEMBL29391346 | 0.93 | CTSD (0.44) | FOLH1ENPEP | |
| SCHEMBL30051366 | 0.91 | ENPEP (0.49) | ENPEP | |
| SCHEMBL30053260 | 0.91 | FOLH1 (0.42) | FOLH1ENPEP | |
| SCHEMBL30052717 | 0.91 | ENPEP (0.47) | FOLH1ENPEP | |
| SCHEMBL30163257 | 0.90 | ENPEP (0.51) | FOLH1ENPEP | |
| SCHEMBL31203047 | 0.89 | FNTA (0.48) | FOLH1ENPEP | |
| SCHEMBL31614420 | 0.89 | BACE1 (0.46) | FOLH1ENPEP | |
| SCHEMBL30051583 | 0.89 | FOLH1 (0.51) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220340887-A1 | Polymerases | SEQULITE GENOMICS US INC (US) | 2022-10-27 | — | — | US | disclosed |
| CN-114402067-A | Polymerase enzyme | 美国赛库莱特生物有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | FOLH1 48/4885ENPEP 18/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | FOLH1 21/4885ENPEP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.